ANAB Logo

AnaptysBio, Inc. (ANAB) 

NASDAQ
Market Cap
$459.17M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
50 of 963
Rank in Industry
41 of 552

Largest Insider Buys in Sector

ANAB Stock Price History Chart

ANAB Stock Performance

About AnaptysBio, Inc.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Insider Activity of AnaptysBio, Inc.

Over the last 12 months, insiders at AnaptysBio, Inc. have bought $10M and sold $5.83M worth of AnaptysBio, Inc. stock.

On average, over the past 5 years, insiders at AnaptysBio, Inc. have bought $32.15M and sold $6.16M worth of stock each year.

Highest buying activity among insiders over the last 12 months: EcoR1 Capital, LLC (10 percent owner) — $60M.

The last purchase of 273,972 shares for transaction amount of $10M was made by EcoR1 Capital, LLC (10 percent owner) on 2024‑08‑14.

List of Insider Buy and Sell Transactions, AnaptysBio, Inc.

2024-11-29Saledirector
10,000
0.0329%
$25.00$250,000-6.35%
2024-09-23SaleChief Medical Officer
1,500
0.0054%
$38.67$58,005-30.85%
2024-09-17SaleCHIEF LEGAL OFFICER
3,780
0.0128%
$38.41$145,191-33.23%
2024-09-16SaleChief Medical Officer
2,220
0.0074%
$38.93$86,425-35.12%
2024-09-16SaleCHIEF LEGAL OFFICER
8,720
0.0297%
$39.82$347,270-35.12%
2024-09-16SaleCHIEF FINANCIAL OFFICER
12,220
0.0417%
$39.91$487,725-35.12%
2024-08-14SaleChief Medical Officer
2,000
0.0088%
$40.00$80,0000.00%
2024-08-14Purchase10 percent owner
273,972
1.095%
$36.50$10M0.00%
2024-07-18SaleChief Medical Officer
1,500
0.0056%
$35.00$52,500-2.50%
2024-07-15Saledirector
10,000
0.0463%
$30.64$306,4220.00%
2024-06-21Saledirector
1,950
0.007%
$23.17$45,182+39.96%
2024-06-18Saledirector
1,950
0.007%
$23.16$45,162+46.35%
2024-05-22SaleCHIEF FINANCIAL OFFICER
1,500
0.0052%
$23.72$35,580+28.15%
2024-03-25SaleCEO
3,000
0.0114%
$21.42$64,268+18.43%
2024-03-22SaleCEO
145,940
0.5734%
$22.78$3.33M+15.13%
2024-02-16SaleCHIEF LEGAL OFFICER
5,000
0.0195%
$25.00$125,000+3.57%
2024-01-30SaleCHIEF FINANCIAL OFFICER
3,065
0.0114%
$23.63$72,425+2.96%
2024-01-08SaleCEO
6,866
0.0251%
$21.81$149,747+7.09%
2024-01-08SaleChief Medical Officer
2,554
0.0093%
$21.81$55,703+7.09%
2024-01-08SaleChief Financial Officer
2,180
0.008%
$21.81$47,546+7.09%

Insider Historical Profitability

29.1%
EcoR1 Capital, LLC10 percent owner
7794996
25.6172%
$15.09100+15.76%
Faga DanielCEO
749087
2.4618%
$15.0903
Lizzul Paul F.Chief Medical Officer
15398
0.0506%
$15.0906
MULROY DENNISCHIEF FINANCIAL OFFICER
4744
0.0156%
$15.0906
LOUMEAU ERIC JCHIEF LEGAL OFFICER
3240
0.0106%
$15.09012
FENTON DENNIS Mdirector
1950
0.0064%
$15.0901
RENTON HOLLINGSdirector
1950
0.0064%
$15.0903
NODELMAN OLEG
7521024
24.7169%
$15.0911+12.85%
Novo Holdings A/S10 percent owner
1936604
6.3644%
$15.0918+58.88%
Topper James N
1045031
3.4344%
$15.0910+58.88%
Frazier Healthcare V, LP10 percent owner
311291
1.023%
$15.0910+58.88%
Frazier Healthcare VII, L.P.10 percent owner
311291
1.023%
$15.0910+58.88%
Lydon Nicholasdirector
271106
0.891%
$15.0911+58.88%
Suria HamzaPresident, CEO
68600
0.2254%
$15.09010
Londei MarcoChief Medical Officer
22377
0.0735%
$15.0903
Ware J. Anthonydirector
3600
0.0118%
$15.0910+16.44%
Avalon Ventures VII L P10 percent owner
0
0%
$15.0901
Piscitelli DominicChief Financial Officer
0
0%
$15.0901

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Ecor1 Capital Llc$169.37M27.537.52M0%+$01.19
BlackRock$38.74M6.31.72M-4.43%-$1.8M<0.01
The Vanguard Group$30.49M4.961.35M-1.89%-$588,042.23<0.01
Tang Capital Management, LLC$29.97M4.871.33M-31.77%-$13.96M0.11
Boxer Capital, LLC$29.28M4.761.3M0%+$00.6
State Street$27.19M4.421.21M+171.72%+$17.18M<0.01
Great Point Partners$22M3.58976,9810%+$03.69
First Light Asset Management$21.26M3.46944,110-23.69%-$6.6M1.79
Frazier Life Sciences Management L P$20.26M3.29899,7000%+$00.92
Point72 Asset Management$19.46M3.16864,100+9.58%+$1.7M0.03
Palo Alto Investors Lp$18.01M2.93799,906+16.45%+$2.55M2.03
Mangrove Partners$15.53M2.52689,521New+$15.53M0.16
Millennium Management LLC$14.57M2.37647,125+58.99%+$5.41M0.01
Morgan Stanley$14.33M2.33636,114+5.66%+$767,526.68<0.01
Saturn V Capital Management Llc$13.2M2.15586,031-11.78%-$1.76M5.29
Deep Track Capital Lp$11.92M1.94529,452-74.01%-$33.95M0.06
Woodline Partners LP$11.46M1.86508,839-57.42%-$15.45M0.1
Dimensional Fund Advisors$10.58M1.72469,860-21.41%-$2.88M<0.01
Franklin Templeton Investments$10.48M1.7465,373+14.87%+$1.36M<0.01
Eventide Asset Management$9.62M1.56427,0000%+$00.16
Geode Capital Management$9.5M1.54421,703+0.38%+$35,995.97<0.01
5Am Venture Management Llc$8.06M1.31357,7330%+$00.54
Blackstone$7.4M1.2328,7200%+$00.03
Citadel Advisors LLC$7.31M1.19324,745+182.45%+$4.72M<0.01
Assenagon Asset Management S.A.$5M0.81221,8380%+$00.01
Northern Trust$4.53M0.74201,149-2.9%-$135,097.50<0.01
D. E. Shaw & Co.$4.21M0.68186,804+16.52%+$596,284.55<0.01
T. Rowe Price$3.87M0.63171,689-25.92%-$1.35M<0.0001
Octagon Capital Advisors LP$3.72M0.6165,000+37.5%+$1.01M0.02
Goldman Sachs$3.39M0.55150,431+7.83%+$246,143.59<0.01
Charles Schwab$3.29M0.54146,271+1%+$32,676.52<0.01
Fidelity Investments$3.17M0.52140,746-30.57%-$1.4M<0.0001
Hudson Bay Capital Management LP$2.98M0.49132,500+39.47%+$844,500.000.02
Two Sigma Advisers LP$2.97M0.48131,700+32.76%+$731,900.000.01
Two Sigma$2.7M0.44119,971+37.06%+$730,571.34<0.01
Renaissance Technologies$2.26M0.37100,200+4.81%+$103,614.77<0.01
Macquarie Group$2.11M0.3493,7320%+$0<0.01
Rafferty Asset Management Llc$2.04M0.3390,694New+$2.04M0.01
Ubs Oconnor Llc$1.87M0.383,025-4.71%-$92,309.480.09
Citigroup$1.78M0.2979,043+2,083.51%+$1.7M<0.01
Fisher Asset Management Llc$1.59M0.2670,654-0.7%-$11,259.99<0.01
PLATINUM INVESTMENT MANAGEMENT LTD$1.49M0.2466,154New+$1.49M0.02
Nuveen$1.45M0.2464,240+20.95%+$250,557.55<0.0001
BNY Mellon$1.44M0.2464,087-8.49%-$133,971.55<0.0001
UBS$1.45M0.2464,166+242.37%+$1.02M<0.0001
Wellington Management Company$1.33M0.2259,048New+$1.33M<0.0001
Bank of America$1.23M0.254,525+114.54%+$655,557.20<0.0001
Susquehanna Fundamental Investments Llc$1.22M0.254,205New+$1.22M0.05
Jacobs Levy Equity Management$1.11M0.1849,389+38.64%+$309,965.20<0.01
Ensign Peak Advisors Inc$978,314.000.1643,4420%+$0<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.